Market research
E4N.F Suda Pharmaceuticals Ltd
F EUR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 14M
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- 0.0%
- Beta
- -1.44
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- Not available
- Market cap
- 14M
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- 0.0%
- Beta
- -1.44
About
About Suda Pharmaceuticals Ltd
Suda Pharmaceuticals Ltd, a biotechnology company, focuses on the development of therapies for the treatment of cancer and conditions that affect the central nervous system in Australia and internationally. The company's product pipeline includes ZolpiMist, an oral spray of zolpidem tartrate to treat short-term insomnia, which is marketed under the brand name of Ambien or Stilnox; Sumatriptan, an oral spray formulation for the treatment of migraine headache; and Anagrelide to treat cancer. It has a license and supply agreement with Cann Pharmaceutical Australia Limited to develop an oral spray of pharmaceutical-grade cannabinoid derivatives for the treatment of drug-resistant epilepsy, melanoma and Sanofi; and collaborative research agreement with Imperial College London. The company was formerly known as Suda Limited and changed its name to Suda Pharmaceuticals Ltd in November 2017. Suda Pharmaceuticals Ltd was incorporated in 1999 and is headquartered in Osborne Park, Australia.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the E4N.F discussion.
5 years, 4 months ago
Suda Pharmaceuticals Ltd is currently in a long term uptrend where the price is trading 74.9% above its 200 day moving average.
From a valuation standpoint, the stock is 98.6% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 18.2.
Suda Pharmaceuticals Ltd's total revenue sank by 0.0% to $192K since the same quarter in the previous year.
Its net income has dropped by 0.0% to $-4M since the same quarter in the previous year.
Finally, its free cash flow fell by 26.3% to $-967K since the same quarter in the previous year.
Based on the above factors, Suda Pharmaceuticals Ltd gets an overall score of 2/5.